Cost Management Insights: SG&A Expenses for Walgreens Boots Alliance, Inc. and Corcept Therapeutics Incorporated

SG&A Expenses: Walgreens vs. Corcept - A Decade of Insights

__timestampCorcept Therapeutics IncorporatedWalgreens Boots Alliance, Inc.
Wednesday, January 1, 20143491600017992000000
Thursday, January 1, 20153694900022400000000
Friday, January 1, 20164524000023910000000
Sunday, January 1, 20176241600023813000000
Monday, January 1, 20188128900024694000000
Tuesday, January 1, 201910035900023557000000
Wednesday, January 1, 202010532600025436000000
Friday, January 1, 202112235600024586000000
Saturday, January 1, 202215284800027295000000
Sunday, January 1, 202318425900034205000000
Monday, January 1, 202428113000000
Loading chart...

Cracking the code

Navigating SG&A Expenses: A Tale of Two Companies

In the ever-evolving landscape of corporate finance, understanding Selling, General, and Administrative (SG&A) expenses is crucial for effective cost management. This analysis delves into the SG&A expenses of Walgreens Boots Alliance, Inc. and Corcept Therapeutics Incorporated from 2014 to 2023. Over this period, Walgreens Boots Alliance consistently reported SG&A expenses exceeding $20 billion annually, reflecting its expansive global operations. In contrast, Corcept Therapeutics, a smaller player, saw its SG&A expenses grow by over 400%, from approximately $35 million in 2014 to $184 million in 2023. This stark difference highlights the scale and operational strategies of these companies. Notably, 2024 data for Corcept is missing, indicating potential reporting delays or strategic shifts. As businesses navigate economic uncertainties, these insights underscore the importance of strategic cost management in maintaining competitive advantage.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025